FidoCure^® Veterinary Team Blog

Soft tissue sarcomas are one of the most common cancers affecting our canine companions. These tumors develop from a variety of soft tissue cells throughout the body, forming masses that pet owners often discover while petting their dogs. Soft tissue sarcomas can appear anywhere on the body but are frequently found on the limbs, trunk, head, and neck. This broad category of tumors includes various subtypes, each originating from different cell types such as muscle, fat, or nerve tissue.

At FidoCure, we're pioneering a revolutionary approach to treating canine cancer by bringing the power of precision medicine from human oncology to veterinary care. If your beloved dog has been diagnosed with cancer, you may have been told that the treatment options are limited. However, thanks to groundbreaking research and innovative technologies, there's new hope in the form of precision cancer drugs originally developed for humans.

Hepatocellular carcinoma (HCC) is the most common primary liver cancer in dogs. It can present as a single mass, multiple nodules, or diffuse spread throughout the liver, which increases the risk of metastasis. The main treatment options are surgical removal, metronomic chemotherapy, and/or Palladia. The prognosis is generally good for the single, massive form after surgery, but consulting a veterinary oncologist is recommended for all cases.

When our beloved pets are diagnosed with cancer, it can be an emotionally and financially challenging time. As veterinary oncology advances, new and innovative cancer treatments are becoming available for our furry family members. However, these cutting-edge therapies can come with a significant price tag.

Nasal adenocarcinomas are relatively uncommon but represent nearly two-thirds of nasal tumors in dogs, which are locally invasive and have a higher risk of metastasis in later stages. Radiation therapy is the primary treatment to slow tumor growth, with patients living around one year on average. Newer approaches like metronomic chemotherapy and precision medicines targeting mutations show promise in delaying progression and metastasis. 

Pulmonary adenocarcinoma is a common and aggressive form of lung cancer in dogs, accounting for nearly 80% of canine lung neoplasia cases. The primary treatment is surgical tumor removal, sometimes combined with chemotherapy or radiation therapy for inoperable cases. Prognosis depends on tumor size and grade, ranging from over 16 months for small, low-grade tumors to only 3 months for high-grade, metastatic cancers despite treatment. 

Happy National Dog Day from all of us at FidoCure! Today, we celebrate the joy, companionship, and unconditional love that dogs bring into our lives. At FidoCure, our mission is to ensure that these beloved companions live longer, happier, and healthier lives, even when faced with the challenge of cancer.

Mast cell tumors are the most common skin tumors in dogs, developing from abnormal growth of mast cells, which are normally involved in allergic and immune responses. Treatment depends on tumor grade, size, and spread, ranging from surgery to radiation therapy to systemic therapies like chemotherapy and/or targeted therapy. Low-grade tumors that are completely removed with surgery carry the best prognosis while high-grade or metastatic tumors often require therapy beyond surgery and carry a more guarded prognosis. As always, consulting a veterinarian or veterinary oncologist is recommended for staging and personalized treatment planning.

FidoCure CEO Christina Lopes will present at the 2024 Animal Health Summit in Kansas City on August 26-27. The summit will showcase emerging companies and foster connections between innovators, investors, and industry leaders in animal health, nutrition, and technology. Attendees can also expect 1:1 business partnering opportunities, interactive experiences, and presentations from some of the world's leading minds in the field.